In this Opinions piece, Clerkenwell Health’s Arda Ozcubukcu discusses the potential value that could be derived from a greater focus on the use of evidence-based psychotherapies in psychedelic research and practice. Below, Arda shares how such an approach may support efforts to prove cost-effectiveness, enable psychedelics to be more easily integrated into existing systems, and more.


Previous articleBetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
Next articleNuminus to Host Q2 2023 Results Conference Call on April 13, 2023